Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction

International Journal of Obesity volume 31, pages 713–717 (2007)Cite this article

Abstract

Background:

Obesity is a very important risk factor for cardiovascular disease, type 2 diabetes mellitus, hypertension, osteoarthritis, fatty liver, metabolic syndrome and respiratory problems. Many weight-reducing drugs cannot be used in obese patients because of numerous complications. Fluoxetine, an antidepressant, and metformin, an antidiabetic drug, reduce weight as their side effect, but the potency of each drug is not always enough. Here, we studied the effects of combination therapy of them for weight reduction in obese women.

Materials and methods:

This study was designed as an open, prospective, controlled clinical trial. Obese and overweight patients referred to obesity clinics were first put under a diet and behavior therapy education program before being invited to this study. The patients who accepted drug therapy were put in the case group. Those who did not accept drug therapy were put in the control group. Fluoxetine, 20 mg daily, and metformin, 500 mg three times daily, were prescribed to the participants. Weight and body mass index (BMI) changes within case and control groups were analyzed by paired t-tests and between groups by t-testing. Side effects were evaluated by interview and questionnaire.

Subjects:

Two hundred and three patients were referred to obesity clinics. Of these, 177 were female with 91 being volunteers for this study. Of this 91, 66 were in the case group and 25 in the control group.

Results:

In a 6.68-month period, a 7.89 kg decrease in weight (9.32%) and a 3.43 U decrease in BMI (10.14%) were observed in participants of the case group that was statistically significant (P<0.0001). The participants of the control group were followed for a mean period of 8.12 months. In this period, the participants of the control group showed a 0.48 kg decrease in weight (0.52%) and a 0.11 U decrease in BMI (0.42%). This was not significant. No serious side effects of the drugs were observed in the case group.

Conclusion:

This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. National Task Force on the Prevention and Treatment of Obesity. Overweight, obesity, health risk. Arch Intern Med 2000; 160: 898–904.

  2. Rosmond R . Aetiology of obesity: a striving after wind? Obes Rev 2004; 5: 177–181.

    Article  CAS  Google Scholar 

  3. Kiortsis DN, Filippatos TD, Elisaf MS . The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes Metab 2005; 31: 15–22.

    Article  CAS  Google Scholar 

  4. O'Meara S, Riemsma R, Shirran L, Mather L, ter Riet G . A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev 2004; 5: 51–68.

    Article  CAS  Google Scholar 

  5. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L . XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–161.

    Article  CAS  Google Scholar 

  6. Darga LL, Carroll-Michals L, Botsford SJ, Lucas CP . Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991; 54: 321–325.

    Article  CAS  Google Scholar 

  7. Krentz AJ, Bailey CJ . Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385–411.

    Article  CAS  Google Scholar 

  8. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S . Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism 2001; 50: 1457–1461.

    Article  CAS  Google Scholar 

  9. Fujioka K . Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical options. Obes Res 2002; 10 (Suppl 2): 116S–123S.

    Article  Google Scholar 

  10. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143–3421.

  11. Poirier P, Despres JP . Exercise in weight management of obesity. Cardiol Clin 2001; 19: 459–470.

    Article  CAS  Google Scholar 

  12. Devlin MJ, Goldfein JA, Petkova E, Jiang H, Raizman PS, Wolk S et al. Cognitive behavioral therapy and fluoxetine as adjuncts to group behavioral therapy for binge eating disorder. Obes Res 2005; 13: 1077–1088.

    Article  Google Scholar 

  13. Halford JC, Harrold JA, Lawton CL, Blundell JE . Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr Drug Targets 2005; 6: 201–213.

    Article  CAS  Google Scholar 

  14. Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003; 5: 180–188.

    Article  CAS  Google Scholar 

  15. Halpern A, Mancini MC . Treatment of obesity: an update on anti-obesity medications. Obes Rev 2003; 4: 25–42.

    Article  CAS  Google Scholar 

  16. Ioannides-Demos LL, Proietto J, McNeil JJ . Pharmacotherapy for obesity. Drugs 2005; 65: 1391–1418.

    Article  CAS  Google Scholar 

  17. Maina G, Albert U, Salvi V, Bogetto F . Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors. J Clin Psychiatry 2004; 65: 1365–1371.

    Article  CAS  Google Scholar 

  18. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Kim C et al. Efficacy of pharmacotherapy for weight loss in adults with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2004; 164: 1395–1404.

    Article  CAS  Google Scholar 

  19. Norris SL, Zhang X, Avenell A, Gregg E, Schmid CH, Lau J . Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 1: CD004096.

    Google Scholar 

  20. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532–546.

    Article  CAS  Google Scholar 

  21. Freemark M, Bursey D . The effects of metformin on body mass index and glucose compliance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001; 107: E55.

    Article  CAS  Google Scholar 

  22. Harborne LR, Sattar N, Norman JE, Fleming R . Metformin and weight loss in obese women with polycystic ovary syndrome: comparison of doses. J Clin Endocrinol Metab 2005; 90: 4593–4598.

    Article  CAS  Google Scholar 

  23. Fuller RW, Wong DT, Robertson DW . Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev 1991; 11: 17–34.

    Article  CAS  Google Scholar 

  24. Fuller RW . Serotonin uptake inhibitors: uses in clinical therapy and in laboratory research. Prog Drug Res 1995; 45: 167–204.

    CAS  PubMed  Google Scholar 

  25. Foltin RW, Haney M, Comer SD, Fischman MW . Effect of fluoxetine on food intake of humans living in a residential laboratory. Appetite 1996; 27: 165–181.

    Article  CAS  Google Scholar 

  26. Munro JF, Scott C, Hodge J . Appraisal of the clinical value of serotoninergic drugs. Am J Clin Nutr 1992; 55 (Suppl 1): 189S–192S.

    Article  CAS  Google Scholar 

  27. Fryer LG, Parbu-Patel A, Carling D . The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem 2002; 277: 25226–25232.

    Article  CAS  Google Scholar 

  28. Hinke SA, Kuhn-Wache K, Hoffmann T, Pederson RA, McIntosh CH, Demuth HU . Metformin effects on dipeptidylpeptidase IV degradation of glucagon-like peptide-1. Biochem Biophys Res Commun 2002; 291: 1302–1308.

    Article  CAS  Google Scholar 

  29. Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S et al. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab 2004; 17: 336–342.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the patients who participated in this study, and the Isfahan Endocrine & Metabolism Research center staff.

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Isfahan University of Medical Sciences,

    M Siavash Dastjerdi, M Mohammady, A Aminorroaya & M Amini

  2. Isfahan Endocrine & Metabolism Research Center, Sedigheh Tahereh Medical Research Complex, Isfahan, Iran

    M Siavash Dastjerdi, M Mohammady, A Aminorroaya & M Amini

  3. Department of Internal Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

    F Kazemi & A Najafian

Authors
  1. M Siavash Dastjerdi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F Kazemi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Najafian
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Mohammady
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Aminorroaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Amini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Siavash Dastjerdi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siavash Dastjerdi, M., Kazemi, F., Najafian, A. et al. An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. Int J Obes 31, 713–717 (2007). https://doi.org/10.1038/sj.ijo.0803447

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803447

Keywords

This article is cited by

Search

Advanced search

Quick links